Doping in sport--1. Excretion of 19-norandrosterone by healthy women, including those using contraceptives containing norethisterone
| Autor: | Vivian H.T. James, Joanne C.Y. Lau, Christopher J. Walker, Andrew T. Kicman, David A. Cowan |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
medicine.medical_specialty Norethisterone Adolescent medicine.medical_treatment Estranes Clinical Biochemistry Population Physiology Biochemistry Gas Chromatography-Mass Spectrometry chemistry.chemical_compound Young Adult Endocrinology Tandem Mass Spectrometry Internal medicine medicine Contraceptive Agents Female Humans education Molecular Biology 19-Norandrosterone Pharmacology Doping in Sports education.field_of_study Pregnancy Progestogen business.industry Organic Chemistry Reproducibility of Results medicine.disease Substance Abuse Detection chemistry Nandrolone Female Norethindrone business Anabolic steroid medicine.drug Hormone |
| Zdroj: | Steroids. 74(3) |
| ISSN: | 0039-128X |
| Popis: | 19-Norandrosterone (19-NA) is the principal urinary metabolite of the anabolic steroid nandrolone and its prohormones. The administration of these 19-nor androgens is prohibited in sport by the World Anti-Doping Agency (WADA) but, even so, adverse findings for 19-NA continue to be commonly reported. Little is known about the urinary concentrations of 19-NA that can occur in women who are not using anabolic steroids, including those using oral contraceptives containing the 19-nor progestogen norethisterone. In 2004, WADA lowered the reporting threshold for 19-NA for females from 5 to 2 ng/mL. The lack of any substantial data on 19-NA excretion in women prompted this large-scale investigation. In this investigation, single untimed urines collected from 1202 female volunteers, 38 of whom were taking norethisterone containing contraceptives, were analysed for 19-NA. None of the women was a competitive athlete and pregnancy had been excluded by a urinary test for human chorionic gonadotropin (hCG). Only one sample exceeded the 19-NA reporting threshold having a concentration of 4.1 ng/mL. This sample was from a user of a norethisterone-containing contraceptive. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect